Eloralintide for Obesity With Type 2 Diabetes
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,035 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
This trial is looking for people with obesity or overweight who also have type 2 diabetes. Participants will take eloralintide or a placebo for about 75 weeks to see if it helps with weight loss.
You may be able to join if
- I have type 2 diabetes
- I have a BMI of 27 or higher
- I have been on stable diabetes treatment for at least 90 days
- I have had no major weight change in the last 90 days
You may not be able to join if
- I have had surgery for obesity within the last year
- I have type 1 diabetes
- I have had a heart attack or stroke in the last 90 days
- I have taken weight loss medications in the last 90 days
- I have a history of serious heart failure
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT